In summary, most studies have demonstrated that high sPD-L1 levels are associated with a worse response to anti-PD-(L)1 immunotherapy, including NSCLC, in direct contradiction to the notion that high PD-L1 levels in the tumor are a good predictive biomarker for NSCLC. Here, SPDL1 is linked to neoplasm.